Streetbeat News

CLRB

Cellectar Biosciences, Inc.

https://www.cellectar.com

Industry

Biotechnology

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Open

2.01

Mkt cap

75M

Volume

1.2M

High

2.02

P/E Ratio

-0.77

52-wk high

4.45

Low

1.83

Div yield

N/A

52-wk low

1.82

Cellectar Biosciences Inc. (NASDAQ:CLRB) stock is trading lower despite meeting the primary endpoint in its CLOVER WaM pivotal study for relapsed/refractory Waldenstrom’s macroglobulinemia. The study showed an overall response rate of 80% and a major response rate of 56.4%, exceeding the primary endpoint of 20% MRR. The company plans to file an FDA marketing application in Q4 2024.

Portfolio Pulse from Vandana Singh

July 23, 2024 | 2:49 pm

Cellectar Biosciences shares are trading lower following the announcement of results from its CLOVER WaM pivotal study evaluating iopofosine I 131.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 11:48 am

Cellectar Biosciences' Iopofosine I 131 has exceeded its primary endpoint in a pivotal study for Waldenstrom's Macroglobulinemia, achieving a 56.4% major response rate and a 98.2% disease control rate in heavily pretreated patients.

Portfolio Pulse from charles@benzinga.com

July 23, 2024 | 10:51 am

Cellectar Biosciences shares are trading higher following the company's announcement regarding the exercise of Tranche B warrants and the purchase of new warrants.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 4:46 pm

Cellectar Biosciences (NASDAQ:CLRB) has generated $19.4M through the exercise of Tranche B warrants and the purchase of new warrants, with the potential to generate an additional $73.3M if the new warrants are exercised.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 10:52 am

Cellectar Biosciences has partnered with City of Hope Cancer Center to focus on the clinical development of its lead radioconjugate asset, Iopofosine I 131, for treating Mycosis Fungoides. The initiation of this development is planned for late 2024 or early 2025.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 10:42 am

Cellectar Biosciences has filed a $300 million mixed securities shelf registration. This move allows the company to offer and sell various types of securities, including common stock, preferred stock, debt securities, and warrants, over time.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 8:49 pm

Cellectar Biosciences reported that as of March 31, 2024, its cash and cash equivalents stood at $40M, which is anticipated to support its operations into the fourth quarter of 2024.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 10:48 am

Cellectar Biosciences reported a Q1 2024 GAAP EPS of $(0.74), missing the estimated $(0.56).

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 10:35 am

Roth MKM analyst Jonathan Aschoff has maintained a Buy rating on Cellectar Biosciences (NASDAQ:CLRB) and increased the price target from $20 to $28.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 5:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.